Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,207 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low Dose Drug A Clear all

Conditions: Opioid-use Disorder, Opioid Dependence
Interventions: Medication Assisted Treatment; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 16 Years to 89 Years
Enrollment: 303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Denver, Colorado • Leawood, Kansas

Conditions: Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
Interventions: palonesetron; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Sunrise, Florida • Galesburg, Illinois • Skokie, Illinois + 6 more

Conditions: Chronic Gout
Interventions: SEL-212 low-dose, SEL-212 high-dose, Normal Saline; Drug · Other
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 40
States / cities: Anniston, Alabama • Sun City, Arizona • Covina, California + 36 more

Conditions: COVID-19
Interventions: FT516; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 76 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hepatitis B
Interventions: Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Sofosbuvir 400 MG [Sovaldi], Ledipasvir 90 MG; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Interventions: TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo, TPI-287 6.3 mg/m2; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 50 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • San Francisco, California

Conditions: Atrial Fibrillation
Interventions: Dronedarone; Drug
Lead sponsor: American Heart Association; Other
Eligibility: 21 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 103
States / cities: Fairhope, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 78 more

Conditions: Breast Cancer
Interventions: trastuzumab (Herceptin®); Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hemophilia, Menstrual Flow Excessive
Interventions: Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.; Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 14 Years to 55 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Colon Cancer, Colorectal Carcinoma, Colon Cleansing
Interventions: NER1006, Trisulfate solution; Drug
Lead sponsor: Norgine; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Anaheim, California • Annapolis, Maryland • Chevy Chase, Maryland + 9 more

Conditions: Norovirus Gastroenteritis
Interventions: VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA Placebo Tablets, VXA-G1.1-NN (low dose) Oral Vaccine Tablet; Biological · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Pre-Eclampsia, Pregnancy Loss
Interventions: Aspirin 162 mg, Aspirin 81mg; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sarcoma
Interventions: celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, conventional surgery, radiation therapy, MESNA, Filgrastim; Drug · Procedure · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 50 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 87
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 78 more

Conditions: Primary Fibromyalgia
Interventions: TNX-102 SL 2.8mg, Placebo; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 17
States / cities: Sacramento, California • Denver, Colorado • Brooksville, Florida + 14 more

Conditions: Alcoholism
Interventions: Perampanel, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Farmington, Connecticut • New Haven, Connecticut • West Haven, Connecticut + 1 more

Conditions: Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome
Interventions: Buprenorphine, Morphine Sulfate; Drug
Lead sponsor: Pediatrix; Other
Eligibility: Up to 1 Year
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Lower Back Pain
Interventions: CNTX-3001, Placebo; Drug
Lead sponsor: Centrexion Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Napa, California

Conditions: Gout
Interventions: Pegloticase, methotrexate, placebo, folic acid, gout flare prophylaxis regimen, fexofenadine, acetaminophen, methylprednisolone; Biological · Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 60
States / cities: Birmingham, Alabama • Anchorage, Alaska • Flagstaff, Arizona + 54 more

Conditions: Contraception
Interventions: Norethindrone acetate/ethinyl estradiol; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,683 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 66
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 52 more

Conditions: Polycystic Ovary Syndrome
Interventions: Orlistat/Meal Replacement/Lifestyle Modification, Loestrin 1/20, Combination of treatments; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 217 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Graft Versus Host Disease, Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: prednisone, methylprednisolone, questionnaire administration; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Non-small Cell Lung Carcinoma
Interventions: Trastuzumab deruxtecan (DS-8201a), Pembrolizumab; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: San Francisco, California • New Haven, Connecticut • Jacksonville, Florida + 6 more

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: Prednisone, Exercise Training on standard steroid regimen, Exercise training on twice-weekly steroids; Drug · Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 5 Years to 9 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pain
Interventions: Morphine, Ketamine; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 65 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Brooklyn, New York

Search by objective public record fields.

Comparing Home, Office, and Telehealth Induction for Medication Assisted Treatment for Opioid Use Disorder

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy

Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia

Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection

Safety Study of TPI-287 to Treat CBS and PSP

Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)

Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence

Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)

Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain

Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout

Study of Safety and Efficacy of an Oral Contraceptive

Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women

Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

Twice Weekly Steroids and Exercise as Therapy for DMD

Geriatric Ketamine for Pain Management Study